Penumbra Q2 Revenue Beats, but Merger Costs and Tax Normalization Weigh on Earnings

summarizeSummary

Penumbra's Q2 revenue of $390M edged past estimates, but net income dropped 23% as merger-related costs and a higher tax rate offset strong sales growth.

check_boxKey Events · Earnings and Guidance · PEN

• Revenue Beats Consensus

  Q2 revenue rose 14.9% to $390.0M, slightly above the $389M consensus, driven by 20% growth in embolization and access products.

• Earnings Decline on Merger Costs

  Net income fell 23% to $34.8M ($0.88/share) as SG&A expenses surged 24.1% to $198.5M, including $6.9M in acquisition-related professional fees for the pending Boston Scientific merger.

• Tax Rate Normalization Hits Bottom Line

  The effective tax rate jumped to 24.6% from 0.1% a year ago due to lower excess tax benefits from stock-based compensation, reducing net income by ~$11M.

• Gross Margin Improves

  Gross margin expanded 190 bps to 67.9%, reflecting favorable product mix across regions.

auto_awesomeAnalysis · PEN · Industrial Applications And Services

Penumbra delivered a solid top-line beat with 14.9% revenue growth to $390M, driven by 20% growth in embolization and access products. However, net income fell 23% year-over-year as SG&A expenses surged 24%, including $6.9M in professional fees tied to the pending $14.5B acquisition by Boston Scientific. The effective tax rate also normalized to 24.6% from near zero a year ago, further pressuring earnings. Gross margins improved to 67.9%, reflecting favorable product mix. The quarter underscores the operational strength of the underlying business, but the merger-related cost overhang and tax headwinds are masking profitability. With the merger expected to close by year-end, these results are largely a placeholder — the real story remains the deal's regulatory progress.